Dr. Hans Wildiers and colleagues published findings from the AIPAC Phase IIb trial (Clin Cancer Res, Feb 2024), evaluating eftilagimod alpha (efti), a soluble LAG-3 protein, in combination with paclitaxel for HR+/HER2- metastatic breast cancer (MBC). While progression-free survival (PFS) was not significantly improved, the study confirmed efti’s immune activation and safety profile. Notably, overall survival (OS) showed improvement in predefined biomarker subgroups, supporting further research into biomarker-driven immunotherapy for endocrine-resistant HR+/HER2- MBC.
This work was made possible by Dr. Wildiers alongside Anne Armstrong, Florence Dalenc, Luc Dirix, Steve Chan, Etienne BRAIN, Sherko Kümmel, and other researchers, reinforcing the role of LAG-3-based therapies in breast cancer treatment.
Read the full study: https://lnkd.in/gb2WszbD
